Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

1.

Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.

Burnett AL, Bivalacqua TJ, Champion HC, Musicki B.

J Sex Med. 2006 Nov;3(6):1077-84.

PMID:
17100941
[PubMed - indexed for MEDLINE]
2.

The efficacy and safety of PDE5 inhibitors.

Rashid A.

Clin Cornerstone. 2005;7(1):47-56. Review.

PMID:
16156423
[PubMed - indexed for MEDLINE]
3.

New achievement and novel therapeutic applications of PDE5 inhibithors in older males.

Frajese GV, Pozzi F.

J Endocrinol Invest. 2005;28(3 Suppl):45-50. Review.

PMID:
16042360
[PubMed - indexed for MEDLINE]
4.

Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.

Burnett AL.

J Androl. 2008 Jan-Feb;29(1):3-14. Epub 2007 Oct 17. Review.

PMID:
17942972
[PubMed - indexed for MEDLINE]
Free Article
5.

2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).

Shindel AW.

J Sex Med. 2009 Jul;6(7):1794-808; quiz 1793, 1809-10. doi: 10.1111/j.1743-6109.2009.01347.x. Review.

PMID:
19575771
[PubMed - indexed for MEDLINE]
6.

Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.

Greco EA, Spera G, Aversa A.

Eur Urol. 2006 Nov;50(5):940-7. Epub 2006 Jul 13. Review. Erratum in: Eur Urol. 2007 Mar;51(3):872.

PMID:
16979814
[PubMed - indexed for MEDLINE]
7.

Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles.

Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A.

Curr Pharm Des. 2006;12(27):3459-65. Review.

PMID:
17017939
[PubMed - indexed for MEDLINE]
8.

The management of phosphodiesterase-5 (PDE5) inhibitor failure.

Lau DH, Kommu S, Mumtaz FH, Morgan RJ, Thompson CS, Mikhailidis DP.

Curr Vasc Pharmacol. 2006 Apr;4(2):89-93. Review.

PMID:
16611151
[PubMed - indexed for MEDLINE]
9.

Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy.

Broderick GA.

J Sex Med. 2012 Jan;9(1):88-103. doi: 10.1111/j.1743-6109.2011.02317.x. Epub 2011 Jun 23. Review.

PMID:
21699659
[PubMed - indexed for MEDLINE]
10.

Phosphodiesterase type 5 regulation in the penile corpora cavernosa.

Lin CS.

J Sex Med. 2009 Mar;6 Suppl 3:203-9. doi: 10.1111/j.1743-6109.2008.01179.x. Review.

PMID:
19267844
[PubMed - indexed for MEDLINE]
11.

Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.

Lombardi G, Macchiarella A, Cecconi F, Del Popolo G.

J Sex Med. 2009 May;6(5):1248-58. doi: 10.1111/j.1743-6109.2008.01205.x. Epub 2009 Feb 9. Review.

PMID:
19210710
[PubMed - indexed for MEDLINE]
12.

The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.

Mehrotra N, Gupta M, Kovar A, Meibohm B.

Int J Impot Res. 2007 May-Jun;19(3):253-64. Epub 2006 Sep 21. Review.

PMID:
16988721
[PubMed - indexed for MEDLINE]
13.

Does testosterone have a role in erectile function?

Mikhail N.

Am J Med. 2006 May;119(5):373-82. Review.

PMID:
16651047
[PubMed - indexed for MEDLINE]
14.

The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development.

Guazzi M, Samaja M.

Curr Med Chem. 2007;14(20):2181-91. Review.

PMID:
17691956
[PubMed - indexed for MEDLINE]
15.

Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.

Aversa A, Bruzziches R, Pili M, Spera G.

Curr Pharm Des. 2006;12(27):3467-84. Review.

PMID:
17017940
[PubMed - indexed for MEDLINE]
16.
17.

The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.

Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H.

Eur Urol. 2007 Nov;52(5):1331-9. Epub 2007 Aug 17. Review.

PMID:
17728050
[PubMed - indexed for MEDLINE]
18.

Pharmacology of erectile dysfunction in man.

Cirino G, Fusco F, Imbimbo C, Mirone V.

Pharmacol Ther. 2006 Aug;111(2):400-23. Epub 2006 Jan 26. Review.

PMID:
16443277
[PubMed - indexed for MEDLINE]
19.

Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application.

Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP.

Eur Urol. 2009 Feb;55(2):334-47. doi: 10.1016/j.eururo.2008.10.028. Epub 2008 Oct 21. Review.

PMID:
18986755
[PubMed - indexed for MEDLINE]
20.

Insights of priapism mechanism and rationale treatment for recurrent priapism.

Yuan J, Desouza R, Westney OL, Wang R.

Asian J Androl. 2008 Jan;10(1):88-101. Review.

PMID:
18087648
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk